Immunology
The Interferon Antiviral Response
Viral RNA sensing, type I interferon, JAK-STAT, and the interferon-stimulated genes that put a cell into an antiviral state
The interferon antiviral response is the cytokine alarm that puts cells into an antiviral state — a first line of defense that acts within hours, long before antibodies exist. A virus-infected cell detects foreign RNA through sensors like RIG-I and the Toll-like receptors, secretes type I interferons (IFN-alpha and IFN-beta), and those cytokines trigger the JAK-STAT pathway in the same and neighboring cells to switch on hundreds of interferon-stimulated genes. The effectors are ruthless: PKR shuts down all protein synthesis, OAS and RNase L shred viral RNA, and the whole tissue is warned before the virus arrives. Interferon was discovered in 1957 by Alick Isaacs and Jean Lindenmann, who named it for the phenomenon of viral interference. The distinct type II interferon, IFN-gamma, is made instead by T cells and NK cells and mainly activates macrophages.
- DiscoveredIsaacs & Lindenmann, 1957
- Type I in humans13 IFN-α + 1 IFN-β
- Shared receptorIFNAR1 / IFNAR2
- SignalingJAK1/TYK2 → STAT1/2 → IRF9
- Genes induced300+ ISGs
- Key effectorPKR halts translation (eIF2α-P)
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
Why the interferon response matters
- It buys time for adaptive immunity. Antibodies and killer T cells take roughly 5 to 10 days to appear after a new infection. The innate interferon response acts within hours, throttling viral replication so the virus does not overwhelm the host before the adaptive response is ready. Interferon is, in effect, the holding action that keeps you alive long enough to make an antibody.
- It creates an antiviral state in whole tissues. Because interferon is a secreted, diffusible cytokine, one infected cell can convert a ring of hundreds of neighbors into a hostile environment for the virus — ribosomes primed to shut down, nucleases ready to fire — before a single virion reaches them.
- Its failure causes lethal disease. Children with inborn errors in the type I IFN pathway (mutations in TLR3, IRF7, IRF9, STAT1, STAT2, or IFNAR) suffer severe or fatal viral infections — herpes simplex encephalitis, disseminated influenza, live-vaccine complications. In 2020 the same genetic and autoantibody defects were shown to underlie a large fraction of critical COVID-19.
- It is a family of approved drugs. Recombinant IFN-alpha treats hepatitis B and C, hairy-cell leukemia, and melanoma; recombinant IFN-beta (Avonex, Rebif, Betaseron) is a mainstay for relapsing-remitting multiple sclerosis. The drugs are literally the body's own antiviral cytokine, mass-produced.
- Too much interferon is also a disease. Chronic overactivity of the type I IFN system drives the type I interferonopathies — Aicardi-Goutières syndrome, STING-associated vasculopathy (SAVI) — and contributes to systemic lupus erythematosus, where an "interferon signature" of constitutively expressed ISGs is a hallmark. The system is a double-edged sword that must be switched off precisely.
- Viruses spend enormous genetic effort defeating it. Almost every successful virus encodes at least one interferon antagonist — influenza NS1, Ebola VP35, SARS-CoV-2 ORF6/NSP1, herpesvirus ICP34.5, poxvirus decoy receptors. The arms race between interferon and viral evasion is one of the clearest examples of host-pathogen coevolution.
How the interferon response works, step by step
The response has two logically separate phases: the induction of interferon by an infected cell, and the response to interferon by that cell and its neighbors. Keeping them separate is the key to understanding the whole system.
Phase 1 — sensing and induction. A cell has no way to see a virus directly, so it watches for molecular signatures that betray one — chiefly nucleic acids in the wrong place or with the wrong chemistry. Cytosolic viral RNA is caught by the RIG-I-like receptors: RIG-I recognizes short double-stranded RNA carrying a 5'-triphosphate, a chemical fingerprint present on many viral genomes but stripped from host mRNA (which is capped), while MDA5 recognizes long double-stranded RNA. Both signal through the mitochondrial adaptor MAVS (also called IPS-1/VISA/Cardif). In endosomes, the Toll-like receptors sample engulfed material: TLR3 senses double-stranded RNA (via the adaptor TRIF), TLR7 and TLR8 sense single-stranded RNA, and TLR9 senses unmethylated CpG DNA (both via MyD88). Cytosolic DNA is detected by cGAS, which synthesizes the cyclic dinucleotide 2'3'-cGAMP to activate the ER adaptor STING. All of these routes converge on a small set of transcription factors — IRF3 and IRF7 (phosphorylated by the kinases TBK1 and IKK-epsilon) together with NF-kB — which assemble on the IFN-beta promoter and switch on transcription of type I interferon.
Phase 2 — the JAK-STAT response. Secreted IFN-alpha/beta diffuses out and binds the two-chain receptor IFNAR1/IFNAR2 on the surface of the same cell (autocrine) and of nearby uninfected cells (paracrine). The receptor chains carry pre-associated Janus kinases — JAK1 on IFNAR2 and TYK2 on IFNAR1. Ligand binding pulls the chains together so the kinases trans-phosphorylate each other and then phosphorylate the receptor tails, creating docking sites for STAT1 and STAT2. The kinases phosphorylate the recruited STATs, which dissociate, pair, and recruit IRF9 to form the trimeric transcription factor ISGF3 (STAT1–STAT2–IRF9). ISGF3 enters the nucleus and binds the interferon-stimulated response element (ISRE) in the promoters of hundreds of interferon-stimulated genes (ISGs), switching them on within minutes to hours.
The effectors. The ISGs are the business end of the response. PKR (protein kinase R) binds viral double-stranded RNA, autophosphorylates, and then phosphorylates eIF2-alpha on serine-51 — trapping the recycling factor eIF2B and shutting down virtually all cap-dependent translation, starving the virus of ribosomes. The OAS/RNase L system: oligoadenylate synthetases, activated by double-stranded RNA, make 2'-5'-linked oligoadenylates that switch on the latent endoribonuclease RNase L, which cleaves both viral and host single-stranded RNA. Mx GTPases (MxA in humans) trap incoming viral nucleocapsids; IFITM proteins block viral membrane fusion at entry; viperin and ISG15 interfere with assembly and act as ubiquitin-like modifiers. Meanwhile the cell upregulates MHC class I to display viral peptides for cytotoxic T cells. If the infection cannot be contained, the same signals push the cell toward apoptosis, sacrificing it to deny the virus a factory.
Type II interferon is a different animal. IFN-gamma is not made by infected cells at all. It is produced by activated T helper 1 cells, cytotoxic T cells, and NK cells, binds a distinct receptor (IFNGR1/IFNGR2 with JAK1 and JAK2), and signals through STAT1 homodimers that bind a different DNA element (the gamma-activated sequence, GAS). Its main job is not antiviral shutdown but immune activation — it licenses macrophages to kill ingested pathogens, boosts antigen presentation by upregulating MHC class I and II, and promotes the Th1 arm of adaptive immunity.
Type I vs type II vs type III interferons
| Feature | Type I (IFN-α/β) | Type II (IFN-γ) | Type III (IFN-λ) |
|---|---|---|---|
| Members (human) | 13 IFN-α, 1 IFN-β, ε, κ, ω | Single IFN-γ | IFN-λ1–4 (IL-28/29 family) |
| Made by | Almost any infected cell; pDCs | Activated T cells, NK, NKT | Epithelial cells, some DCs |
| Receptor | IFNAR1 / IFNAR2 | IFNGR1 / IFNGR2 | IFNLR1 / IL10RB |
| Kinases | JAK1 + TYK2 | JAK1 + JAK2 | JAK1 + TYK2 |
| Transcription factor | ISGF3 (STAT1-STAT2-IRF9) | GAF (STAT1 homodimer) | ISGF3 (same as type I) |
| DNA element | ISRE | GAS | ISRE |
| Main role | Antiviral state, systemic | Macrophage / immune activation | Antiviral at barrier surfaces |
| Receptor spread | Nearly ubiquitous | Broad on immune cells | Restricted to epithelia |
Sensing and induction vs the JAK-STAT response
| Property | Induction (making interferon) | Response (reading interferon) |
|---|---|---|
| Trigger | Viral RNA / DNA inside the cell | Secreted IFN binding its receptor |
| Sensors | RIG-I, MDA5, TLR3/7/8/9, cGAS | IFNAR1 / IFNAR2 (type I) |
| Adaptors | MAVS, TRIF, MyD88, STING | JAK1, TYK2 (receptor-associated) |
| Transcription factors | IRF3, IRF7, NF-κB | ISGF3 (STAT1-STAT2-IRF9) |
| DNA element bound | PRDs of the IFN-β enhanceosome | ISRE in ISG promoters |
| Output | Type I interferon secreted | 300+ interferon-stimulated genes |
| Who does it | The infected cell | Infected cell + neighbors (paracrine) |
| Effect | Broadcasts the alarm | Builds the antiviral state; PKR, OAS/RNase L, Mx, IFITM |
Common misconceptions
- "Interferon kills viruses directly." It does not touch a virus. Interferon is a signaling cytokine that instructs cells to express antiviral effector proteins. The killing is done downstream by PKR, RNase L, Mx, IFITM, and by the cell shutting down its own translation. Interferon is the alarm, not the weapon.
- "IFN-gamma is just another antiviral interferon." Despite the shared name, IFN-gamma (type II) is functionally distinct: it is made by lymphocytes, not infected cells, signals through STAT1 homodimers rather than ISGF3, and mainly activates macrophages and boosts antigen presentation. Its antiviral action is largely indirect.
- "The cell that senses the virus is the one that's protected." The dying infected cell often cannot save itself — its power is that it warns the neighborhood. Paracrine interferon protects the surrounding uninfected cells, which is the whole point of a diffusible cytokine.
- "Interferon only matters for RNA viruses." DNA viruses are sensed too. The cGAS-STING pathway detects cytosolic viral DNA and induces the same type I interferons; this branch is central to defense against herpesviruses and is also how DNA-based vaccines and some tumor DNA trigger interferon.
- "More interferon is always better." Chronic type I IFN signaling causes autoimmune interferonopathies (Aicardi-Goutières syndrome, SAVI) and drives the interferon signature in lupus. Persistent interferon during chronic infections like LCMV or HIV can even exhaust T cells and impair clearance. The system is calibrated to switch off, and negative regulators (SOCS1, USP18, and receptor down-modulation) are as important as the activators.
- "PKR only stops the virus." PKR halts all cap-dependent translation, host and viral alike. It is a scorched-earth tactic: the infected cell sacrifices its own protein synthesis to deny ribosomes to the virus, which is why so many viruses carry dedicated PKR antagonists (influenza NS1, vaccinia K3L, HCV via its own mechanisms).
Famous experiments and history
- Isaacs and Lindenmann (1957). Working at London's National Institute for Medical Research, Alick Isaacs and Jean Lindenmann incubated chick chorioallantoic membrane with heat-inactivated influenza and found the tissue secreted a soluble factor that made fresh cells resistant to live virus. They named it interferon, after the known phenomenon of viral interference. Their papers in Proceedings of the Royal Society B launched the field.
- Cloning the interferon genes (~1980). Interferon was notoriously hard to purify — for two decades it was almost mythical. Charles Weissmann's group cloned human IFN-alpha and Tadatsugu Taniguchi cloned human IFN-beta around 1980, proving interferon was a real protein and enabling recombinant production. This turned interferon from a curiosity into a manufacturable drug within a few years.
- The JAK-STAT pathway (early 1990s). James Darnell, Ian Kerr, and George Stark dissected how interferon signals into the nucleus. Using interferon-unresponsive mutant cell lines, they identified the STAT transcription factors and the Janus kinases, mapping the ISGF3 complex and the ISRE. The paradigm they built — receptor-associated kinase phosphorylates a latent cytoplasmic transcription factor that then goes to the nucleus — became the template for dozens of cytokine pathways.
- RIG-I as the cytosolic RNA sensor (2004). Takashi Fujita and Shizuo Akira's groups identified RIG-I and MDA5 as the cytosolic receptors that detect viral RNA and trigger interferon, filling in how a cell sees a virus in its own cytoplasm — a discovery that reshaped innate immunity.
- Interferon defects in severe COVID-19 (2020). Two Science papers from the COVID Human Genetic Effort (Jean-Laurent Casanova and colleagues) showed that inborn errors in the type I IFN pathway accounted for roughly 3 to 4 percent of critical COVID-19 pneumonia, and that at least 10 percent of critically ill patients harbored pre-existing neutralizing autoantibodies against their own type I interferons — a dramatic, real-time demonstration that a working interferon response in the first days of infection is a matter of life and death.
Frequently asked questions
What is the difference between type I, type II, and type III interferons?
Type I interferons are the classic antiviral cytokines: 13 IFN-alpha subtypes plus a single IFN-beta (and IFN-epsilon, IFN-kappa, IFN-omega) in humans, made by almost any infected cell and by plasmacytoid dendritic cells. They all bind one receptor, IFNAR1/IFNAR2, and drive the antiviral state through STAT1-STAT2-IRF9. Type II is a single cytokine, IFN-gamma, made only by activated T cells, NK cells, and NKT cells, not by infected cells; it binds a distinct receptor (IFNGR1/IFNGR2), signals through STAT1 homodimers, and is chiefly an immune-activating cytokine — it licenses macrophages to kill intracellular pathogens and upregulates MHC class I and II. Type III interferons (IFN-lambda 1-4, the IL-28/IL-29 family) do the same antiviral job as type I but signal through the IFNLR1/IL10RB receptor, which is restricted mostly to epithelial cells at barrier surfaces like the gut and airway, giving a more localized, less inflammatory response.
How does a cell know it is infected by a virus?
Cells recognize molecular signatures of viruses called pathogen-associated molecular patterns, mostly foreign nucleic acids, using germline-encoded pattern-recognition receptors. In the cytosol, the RIG-I-like receptors RIG-I and MDA5 detect viral RNA: RIG-I binds short double-stranded RNA bearing a 5'-triphosphate (a hallmark of viral genomes never found on capped host mRNA), while MDA5 senses long double-stranded RNA. Both then signal through the mitochondrial adaptor MAVS. In endosomes, Toll-like receptors sample engulfed material: TLR3 detects double-stranded RNA, TLR7 and TLR8 detect single-stranded RNA, and TLR9 detects unmethylated CpG DNA, signaling through TRIF or MyD88. Cytosolic DNA is caught by cGAS, which makes the second messenger cGAMP to activate STING. All of these routes converge on the transcription factors IRF3, IRF7, and NF-kB to switch on interferon.
How does the JAK-STAT pathway turn on antiviral genes?
When secreted type I interferon binds the two-chain receptor IFNAR1/IFNAR2 on a cell surface, the receptor's associated Janus kinases — JAK1 on IFNAR2 and TYK2 on IFNAR1 — are brought together and trans-phosphorylate each other. The activated kinases then phosphorylate tyrosine residues on the receptor tails, creating docking sites for STAT1 and STAT2. The kinases phosphorylate the recruited STATs, which dissociate, pair up, and recruit a third factor, IRF9, to form the trimeric ISGF3 complex. ISGF3 translocates to the nucleus and binds a DNA motif called the interferon-stimulated response element (ISRE) in the promoters of hundreds of interferon-stimulated genes, switching them on within minutes to hours. IFN-gamma uses the same logic but forms STAT1 homodimers (called GAF) that bind a different element, the gamma-activated sequence (GAS).
What does PKR do during a viral infection?
PKR (protein kinase R, gene EIF2AK2) is one of the most important interferon-stimulated effectors. It is made in an inactive form and is switched on when it binds viral double-stranded RNA, which causes it to dimerize and autophosphorylate. Active PKR then phosphorylates serine-51 on the alpha subunit of eukaryotic initiation factor 2 (eIF2-alpha). Phosphorylated eIF2-alpha traps the guanine-exchange factor eIF2B, blocking the recycling of eIF2-GDP to eIF2-GTP that every round of translation initiation requires. The result is a near-total shutdown of protein synthesis in the infected cell. Because viruses are obligate parasites that hijack host ribosomes to make their own proteins, halting translation starves the virus of the machinery it needs to replicate — even at the cost of the host cell's own proteins. Many viruses carry dedicated PKR antagonists, such as influenza NS1 and vaccinia K3L, precisely because PKR is so effective.
How do interferons warn neighboring cells before the virus reaches them?
Interferon is a secreted, diffusible cytokine, so it acts both on the cell that made it (autocrine) and on nearby uninfected cells (paracrine). An infected cell may die within hours, but before it does it releases a burst of IFN-alpha/beta that spreads through the tissue faster than the virus can. Neighboring cells that have not yet been infected bind that interferon on their IFNAR receptors, activate JAK-STAT, and pre-emptively express the antiviral arsenal — PKR, OAS/RNase L, Mx GTPases, IFITM proteins, and viperin — before any virus particle arrives. This raises the antiviral state, effectively vaccinating a ring of tissue against the incoming infection so that when a virion does enter, it finds ribosomes already primed to shut down and RNA-degrading enzymes ready to fire. This paracrine early-warning is why interferon buys the days the adaptive immune system needs to mount an antibody and T-cell response.
Who discovered interferon and how?
Interferon was discovered in 1957 by Alick Isaacs and Jean Lindenmann at the National Institute for Medical Research in London. They were studying viral interference — the long-known observation that infection with one virus can protect a cell from a second virus. Incubating chick chorioallantoic membranes with heat-inactivated influenza virus, they found the tissue released a soluble factor into the medium that made fresh cells resistant to live virus. They named the substance interferon after the phenomenon of interference. The finding was met with skepticism (some dubbed it 'misinterpreton') because the factor was hard to purify, but it was vindicated: human IFN-beta and IFN-alpha genes were cloned around 1980 by groups including Charles Weissmann and Tadatsugu Taniguchi, enabling recombinant production. Recombinant interferons are now approved drugs — IFN-alpha for hepatitis B and C and some cancers, and IFN-beta for relapsing multiple sclerosis.
Why do some patients get severe COVID-19 because of interferon problems?
A landmark pair of 2020 Science papers from the COVID Human Genetic Effort showed that faults in the type I interferon system are a major cause of life-threatening COVID-19. In one study, about 3 to 4 percent of patients with critical pneumonia carried rare loss-of-function mutations in genes of the type I IFN pathway, such as TLR3, IRF7, and IFNAR1. In a second study, at least 10 percent of critically ill patients had pre-existing neutralizing autoantibodies against their own type I interferons — mostly IFN-alpha and IFN-omega — that were essentially absent in people with mild disease. In both cases the shared mechanism is a blunted or missing early interferon response, letting SARS-CoV-2 replicate unchecked in the first days of infection. These autoantibodies are more common in older men, which helps explain part of the age and sex skew in COVID-19 mortality.